Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
|Articles|January 27, 2021
Supplements and Featured Publications
- Value-Based Agreements in Rare Disease: Focus on Hereditary Amyloid Transthyretin Amyloidosis
Value-Based Agreements in Rare Disease: Focus on Hereditary Amyloid Transthyretin Amyloidosis
Advertisement
The American Journal of Managed Care® hosted a scientific interchange titled “Value-Based Agreements in Rare Disease” on September 30, 2020. This publication highlights key discussion points and insights from this event.
Advertisement
Related to this article
Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.
Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.
A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.
Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
3
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5